Cargando…
Prediction of clinically relevant hyperkalemia in patients treated with peptide receptor radionuclide therapy
BACKGROUND: Peptide receptor radionuclide therapy (PRRT) is applied in patients with advanced neuroendocrine tumors. Co-infused amino acids (AA) should prevent nephrotoxicity. The aims of this study were to correlate the incidence of AA-induced hyperkalemia (HK) (≥5.0 mmol/l) and to identify predict...
Autores principales: | Lapa, Constantin, Werner, Rudolf A, Bluemel, Christina, Lueckerath, Katharina, Muegge, Dirk O, Strate, Alexander, Haenscheid, Heribert, Schirbel, Andreas, Allen-Auerbach, Martin S, Bundschuh, Ralph A, Buck, Andreas K, Herrmann, Ken |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4412196/ https://www.ncbi.nlm.nih.gov/pubmed/25977880 http://dx.doi.org/10.1186/s13550-014-0074-y |
Ejemplares similares
-
Influence of the amount of co-infused amino acids on post-therapeutic potassium levels in peptide receptor radionuclide therapy
por: Lapa, Constantin, et al.
Publicado: (2014) -
Somatostatin receptor expression in small cell lung cancer as a prognostic marker and a target for peptide receptor radionuclide therapy
por: Lapa, Constantin, et al.
Publicado: (2016) -
Survival prediction in patients undergoing radionuclide therapy based on intratumoral somatostatin-receptor heterogeneity
por: Werner, Rudolf A., et al.
Publicado: (2016) -
Novel CYP11B-ligand [(123/131)I]IMAZA as promising theranostic tool for adrenocortical tumors: comprehensive preclinical characterization and first clinical experience
por: Heinze, Britta, et al.
Publicado: (2021) -
Peptide receptor radionuclide therapy as a new tool in treatment-refractory sarcoidosis - initial experience in two patients
por: Lapa, Constantin, et al.
Publicado: (2018)